ST-067 and Teclistamab
Phase 1b Study of ST-067 (Decoy-Resistant IL-18) With Teclistamab in Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 20 patients (estimated)
- Sponsors
- Fred Hutchinson Cancer Research Center
- Collaborators
- Simcha Therapeutics
- Tags
- Interleukin 18 (IL-18)
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 2028
- NCT Identifier
- NCT06588660
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.